Self-reported medication adherence and treatment satisfaction in patients with epilepsy

Sweileh, Waleed M.; Ihbesheh, Manal S.; Jarar, Ikhlas S.; Taha, Adham S. Abu; Sawalha, Ansam F.; Zyoud, Sa’ed H.; Jamous, Raniah M.; Morisky, Donald E.

doi:10.1016/j.yebeh.2011.04.011

Cited by 145 publications

(148 citation statements)

References 33 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Our findings regarding the influence of AED therapy type on the extent of adherence are in agreement with those of Sweileh et al (20) Both studies showed no significant difference in medication adherence between patients on monotherapy and those on polytherapy. In contrast, the studies by Gabr and Shams, (17) Bautista and Rundle-Gonzalez (21) and Harimanana et al (22) found that patients on monotherapy were significantly more adherent to medication than those who were on polytherapy.…”

Section: Discussionsupporting

confidence: 93%

An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study

Gurumurthy

Kulkarni

Sarma

2017

smedj

View full text Add to dashboard Cite

INTRODUCTIONEpilepsy affects 70 million people worldwide.(1) Long-term antiepileptic drug (AED) administration remains the mainstay of epilepsy treatment. In up to 67% of patients with epilepsy (PWE), AEDs effectively eliminate or reduce the frequency of seizures.(2) Medication adherence refers to the extent to which a patient's behaviour corresponds with the recommendations of a health professional. Medication adherence is usually better when there is greater patient involvement in the treatment choice, as well as cooperation and mutual agreement between the health provider and the patient.(2) Nonadherence rates among PWE are reported to be 30%-50%.(3) It is well established that patients with suboptimal adherence levels are more likely to have seizures that are associated with increased number of hospital admissions and healthcare costs.(4) Factors influencing adherence to AEDs have been described; these include patient-, treatment-and health system-related factors.(5) The promotion of medication adherence is considered to be an important component of pharmaceutical care practice. Several methods have been used to measure therapeutic adherence, including self-report, pill count, appointment attendance, medication refill history, blood or urine drug levels and drug diary.(6) Indirect methods, such as self-reports and patient interviews, are the simplest and most common methods used for measuring medication adherence. (7,8) To date, most of the studies conducted to evaluate AED adherence among PWE did not account for the influence of a wide range of variables (e.g. demographic, disease and treatment patterns). There are not many studies in the Indian literature that examine the factors that influence AED adherence. Identifying the factors associated with AED adherence would allow the development of strategies to improve adherence. Thus, the present study aimed to evaluate the pattern and extent of AED adherence among PWE and to identify the factors that influence adherence. METHODSThis cross-sectional study was conducted by the Division of Clinical Pharmacology at the outpatient and inpatient clinics of the Department of Neurology, St John's Medical College and Hospital, Bangalore, India, over a period of 1.5 years (January 2012 to July 2013). Ethical approval was obtained from the institution's Ethical Review Board. Patients aged ≥ 18 years who were receiving AED treatment were eligible for inclusion in the study. Only those who gave their consent for participation were enrolled. Pregnant or lactating women and patients with comorbidities were excluded from the study.Data was collected using a specially designed case record form that included items on demographic/family history, seizure history, duration of epilepsy, AEDs prescribed and occurrence of

show abstract

Section: Discussionsupporting

confidence: 93%

An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study

Gurumurthy

Kulkarni

Sarma

2017

smedj

View full text Add to dashboard Cite

show abstract

“…There was a significant difference in adherence between patients on mono and polytherapy. This was in agreement with Sweileh et al [18]. Other factors such as patient gender, age, marital status, education, comorbidities, type of epilepsy [19], age of onset, seizure frequency, last episode, and problems related to therapy did not significantly affect patient medication adherence.…”

Section: Ayswarya and Kumarsupporting

confidence: 92%

“…77% patients were nonadherent to the therapy in our study. On the other hand, Sweileh et al found that 64% of the patients were nonadherent [18]. While 38.3% were nonadherent reported by Gabr and Shams in 2014 [16].…”

Section: Ayswarya and Kumarmentioning

confidence: 94%

A Prospective Study on Impact of Patient Counselling on Quality of Life and Medication Adherence in Epileptic Patients

Kumar

Ayswarya²

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: To study the impact of patient counseling on medication adherence and quality of life (QOL) in epileptic patients and to assess the factors affecting medication adherence.Methods: This study is a prospective observational study involving 100 patients with an age limit of 8-60 years and those taking Antiepileptic drugs for at least 3 months. The study population received patient counseling during their first visit. The impact of patient counseling on QOL and medication adherence was assessed using self-reported questionnaire QOLIE-31 and MMAS-8 between the first visit and the second visit. Statistical analysis (Paired t-test and Paired Chi-square test) was performed to analyze the impact of patient counseling on QOL and medication adherence in epileptic patients. Results:A total of 100 patients were included in the study. After providing patient counseling, it was observed that there was a statistically significant (p<0.05) improvement in all domains of QOLIE-31 and MMAS-8 scores. Before counseling, mean overall T-score of QOLIE-31 was 44.08±2.07which was changed to 49.14±1.27 after patient counseling with a mean change of 5.06 in overall T-score. In the case of medication adherence, before counseling 77% subjects were nonadherent to therapy, after counseling it was reduced to 41%. The common reasons for medication adherence were forgetfulness, unawareness, therapy related, and economics related. Out of which forgetfulness along with unawareness was the major one. Conclusion:The study described that patient counseling plays a major role in improving QOL and medication adherence.

show abstract

“…The subjective results reported on the TSQM were concordant with the objectively reported AEs recorded in subject diaries. Improved treatment satisfaction is believed to increase compliance and treatment effectiveness [14,39]. Treatment satisfaction can be measured using a standardized self-reported measurement of outcome comparing patients' subjective treatment experience with subjective standards [14,40].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency

Niebur

Duff

Shear

et al. 2015

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Multiple subcutaneous immunoglobulin (SCIG) products are available to treat primary antibody deficiency (PAD). The efficacy and tolerability of 16% SCIG (Vivaglobin®) was compared with 20% SCIG (Hizentra®) in PAD subjects. The study was a prospective, single‐centre, open‐label study of PAD subjects transitioning Vivaglobin to equivalent Hizentra doses, rounded to the nearest vial size. Comparisons included immunoglobulin (Ig)G levels; tetanus, varicella and Streptococcus pneumoniae titres; adverse events (AEs), annual infection rate and quality of life during 8 weeks of Vivaglobin and 24 weeks of Hizentra. Thirty‐two subjects (aged 2–75 years) participated. Rounding to the nearest Hizentra vial size resulted in a 12·8% (± 2·9%) increase in SCIG dose. Median immunoglobulin (Ig)G level following 8 weeks of Vivaglobin was similar to 24 weeks of Hizentra (1050 versus 1035 mg/dl, respectively; P = 0·77). Both products had similar protective titres to tetanus, varicella and serotypes of S. pneumoniae, which were variable but well above protective levels. After 12 weeks of Hizentra, subjects reported fewer local site reactions compared with Vivaglobin. Switching products resulted in increased systemic AEs in some subjects but, overall, not significantly higher than during Vivaglobin treatment. Average infusion time decreased from 104·7 min (3·3 sites) with Vivaglobin to 70·7 min (2·2 sites) with Hizentra (P = 0·0005). Acute serious bacterial infections were similar. Treatment satisfaction was superior with Hizentra. Hizentra and Vivaglobin have similar pharmacokinetics and efficacy. Although transition to a different SCIG product initially increased AEs, Hizentra is well tolerated and can be infused more rapidly and with fewer sites compared to Vivaglobin.

show abstract

Self-reported medication adherence and treatment satisfaction in patients with epilepsy

Cited by 145 publications

References 33 publications

An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study

An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study

A Prospective Study on Impact of Patient Counselling on Quality of Life and Medication Adherence in Epileptic Patients

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency

Contact Info

Product

Resources

About